TITLE:
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

CONDITION:
Hepatitis C, Chronic

INTERVENTION:
Copegus

SUMMARY:

      This study will evaluate the efficacy and safety of different durations of treatment with
      PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have
      never previously received interferon (IFN) therapy. The anticipated time on study treatment
      is 3-12 months and the target sample size is 500+ individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  patients >=18 years of age;

          -  CHC infection (genotype 2 or 3);

          -  liver biopsy (in <24 calendar months of first dose), with results consistent with CHC
             infection;

          -  use of 2 forms of contraception during study and 6 months after the study in both men
             and women.

        Exclusion Criteria:

          -  women who are pregnant or breastfeeding;

          -  male partners of women who are pregnant;

          -  conditions associated with decompensated liver disease;

          -  other forms of liver disease, including liver cancer;

          -  human immunodeficiency virus infection;

          -  previous treatment with an IFN, pegylated IFN, ribavirin, viramidine, levovirin, or
             amantadine.
      
